Back to dashboard
CommercialCoverageMedium impact

08.02.45, Telisotuzumab vedotin-tllv (Emrelis™)

Independence Blue Cross·Oncology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

A new pharmacy policy has been established for Telisotuzumab vedotin-tllv (Emrelis™), a specialty medication. This creates new coverage guidelines and likely establishes prior authorization requirements for this oncology drug.

Action Required

Action needed
By October 1, 2025: Billing team must review the full policy details at the provided URL to understand coverage criteria and prior authorization requirements for Telisotuzumab vedotin-tllv (Emrelis™). Update billing system with any required prior auth rules and inform oncology providers of new coverage guidelines.

Related policy hubs